GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Tourmaline Bio Inc (NAS:TRML) » Definitions » Change In Inventory

Tourmaline Bio (Tourmaline Bio) Change In Inventory : $0.00 Mil (TTM As of Mar. 2024)


View and export this data going back to 2023. Start your Free Trial

What is Tourmaline Bio Change In Inventory?

Tourmaline Bio's change in inventory for the quarter that ended in Mar. 2024 was $0.00 Mil. It means Tourmaline Bio's inventory stayed the same from Dec. 2023 to Mar. 2024 .

Tourmaline Bio's change in inventory for the fiscal year that ended in Dec. 2023 was $0.00 Mil. It means Tourmaline Bio's inventory stayed the same from Dec. 2022 to Dec. 2023 .

Tourmaline Bio's Total Inventories for the quarter that ended in Mar. 2024 was $0.00 Mil.

Days Inventory indicates the number of days of goods in sales that a company has in the inventory.

Inventory Turnover measures how fast the company turns over its inventory within a year.

Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue.


Tourmaline Bio Change In Inventory Historical Data

The historical data trend for Tourmaline Bio's Change In Inventory can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Tourmaline Bio Change In Inventory Chart

Tourmaline Bio Annual Data
Trend Dec21 Dec22 Dec23
Change In Inventory
- - -

Tourmaline Bio Quarterly Data
Dec21 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Change In Inventory Get a 7-Day Free Trial Premium Member Only - - - - -

Tourmaline Bio Change In Inventory Calculation

Change In Inventory is the difference between last period's ending inventory and the current period's ending inventory.

Change In Inventory for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.00 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Tourmaline Bio  (NAS:TRML) Change In Inventory Explanation

1. Days Inventory indicates the number of days of goods in sales that a company has in the inventory.

Tourmaline Bio's Days Inventory for the quarter that ended in is calculated as:

2. Inventory Turnover measures how fast the company turns over its inventory within a year.

Tourmaline Bio's Inventory Turnover for the quarter that ended in Mar. 2024 is calculated as

3. Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue.

Tourmaline Bio's Inventory to Revenue for the quarter that ended in Mar. 2024 is calculated as

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Tourmaline Bio Change In Inventory Related Terms

Thank you for viewing the detailed overview of Tourmaline Bio's Change In Inventory provided by GuruFocus.com. Please click on the following links to see related term pages.


Tourmaline Bio (Tourmaline Bio) Business Description

Traded in Other Exchanges
N/A
Address
27 West 24th Street, Suite 702, New York, NY, USA, 10010
Tourmaline Bio Inc is a late-stage clinical biotechnology company driven by its mission to develop transformative medicines that dramatically improve the lives of patients with life-altering immune diseases. Its initial product candidate is TOUR006, a fully human monoclonal antibody that selectively binds to interleukin-6 (IL-6), a key proinflammatory cytokine involved in the pathogenesis of many autoimmune and inflammatory disorders. The anti-IL-6 and anti-IL-6 receptor (IL-6R) antibody class (IL-6 class) has over two decades of clinical and commercial experience treating over a million patients with a variety of autoimmune and inflammatory diseases.